Omega Healthcare Investors (NYSE: OHI) reported Q2 EPS of $0.46, $0.02 better than the analyst estimate of $0.44. Revenue for the quarter came in at $282.51 million versus the consensus estimate of $240.6 million.

2025 AFFO GUIDANCE INCREASED

The Company increased its expected 2025 AFFO range to be between $3.04 to $3.07 per diluted share from the previous range of $2.95 to $3.01 per diluted share. The Company\'s revised AFFO guidance for 2025 includes $605 million in new real property and loan investments completed year-to-date through June 2025. It also assumes quarterly G&A expense of approximately $13.5 million to $14.5 million, the repayment of $600 million of 5.250% senior unsecured notes due in January 2026, on October 15, 2025, the repayment of a $251.6 million GBP denominated secured mortgage loan on November 25, 2025, and no material changes in market interest rates. In addition, it assumes that no additional operators are placed on a cash-basis for revenue recognition, Genesis and Avardis continue to pay their full contractual obligations as outlined above, and that Maplewood continues to pay rent at $6.1 million per month. The guidance assumes no material change in foreign currency exchange rates due to derivative instruments entered into to minimize the fluctuation in the GBP spot rates. The Company holds $233 million mortgages and other real estate-backed investments that are set to mature in 2025. The revised guidance assumes that $65 million of these investments will be converted from loans to fee simple real estate, $88 million will be repaid by the end of 2025, and the remaining balance will be extended beyond 2025. The guidance includes approximately $50 million in asset sales; however, it excludes any additional acquisitions, certain revenue and expense items, interest refinancing expenses, acquisition costs, capital markets activity and additional provisions for credit losses, if any.

For earnings history and earnings-related data on Omega Healthcare Investors (OHI) click here.